Chiesi Farmaceutici to acquire biopharma company Amryt Pharma for $1.5bn
Chiesi Farmaceutici, an Italian biopharmaceuticals and healthcare group, has agreed to acquire Amryt Pharma, a commercial-stage biopharmaceutical company, in an all-cash transaction valued at around ... Read More
Amryt gets FDA orphan drug designation for Mycapssa for carcinoid syndrome
Amryt, a commercial-stage biopharma company, has secured orphan drug designation for Mycapssa (octreotide capsules) from the US Food and Drug Administration (FDA) for the treatment ... Read More